PlainPharmaWatch

CMS Open Payments · Program Year 2024

Astellas US Technologies

Astellas US Technologies reported $6,859,578.00 across General Payments, Research, and Ownership to 0 physicians and teaching hospitals across 49 transactions.

See the rankings → How this is sourced
$6.9M Top quartile payer
All-tracks total
49 Below-median volume
Transactions
0 —
Recipients
#224
of 1,925 companies

Astellas US Technologies reported $6,859,578.00 across all CMS Open Payments tracks (General + Research + Ownership) to 0 physicians and teaching hospitals in Program Year 2024 - ranking #224 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total), averaging $0.00 per recipient.

Astellas US Technologies's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

42/100

Total payments

C

73/100

Transaction volume

F

10/100

Physician reach and Payment type diversity not applicable for Astellas US Technologies - no recorded activity on that dimension; its weight was redistributed to the applicable dimensions above.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer astellas-us-technologies Astellas US Technologies

$6.9M · #224/1,925 · 0.0% industry · PY2024

  • TOT $6.9M
  • RANK #224
  • SHARE 0.0%
  • TXN 49
  • RCP 0
  • CAT 0
  • GEN n/a
  • PY 2024

Volume peers

Nearest volume peer: Astellas Pharma Inc ($6.9M)

Dompe Farmaceutici S.p.A.$6.9MAstellas Pharma Inc$6.9MAstellas US Technologies (th…$6.9MJohnson & Johnson Vision Car…$6.8MAptis Medical, LLC$6.8M
All-tracks payment totals near Astellas US Technologies (CMS Open Payments PY2024)

Astellas US Technologies sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Astellas US Technologies

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Astellas US Technologies that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

The 0-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). Payments are distributed across multiple categories without a dominant single type.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Astellas US Technologies.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Astellas US Technologies ranks #224 of 1,925 by all-tracks total payments.

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Astellas US Technologies's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.